Structure via PubChem · Public domain (PubChem)
aplindore
Sign in to saveAlso known as DAB-452
Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the dopamine receptor D2. It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome.
Chemical data
- Formula
- C18H18N2O3
- Molecular weight
- 310.3 g/mol
- IUPAC name
- (2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one
- SMILES
- C1[C@@H](OC2=C(O1)C=CC3=C2CC(=O)N3)CNCC4=CC=CC=C4
- InChIKey
- DYJIKHYBKVODAC-ZDUSSCGKSA-N
- XLogP
- 1.6
- Polar surface area
- 59.6 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 310.131742436
Show 4 more facts
- Commons category
- Aplindore
- canonical SMILES
- C1C(OC2=C(O1)C=CC3=C2CC(=O)N3)CNCC4=CC=CC=C4
- isomeric SMILES
- C1[C@@H](OC2=C(O1)C=CC3=C2CC(=O)N3)CNCC4=CC=CC=C4
- chemical formula
- C₁₈H₁₈N₂O₃
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the dopamine receptor D2. It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome.
On December 23, 2009 Neurogen was acquired by Ligand Pharmaceuticals. Rights to Aplindore were given to Ligand around time of merger. As of 2008, Phase II was completed and Ligand.
Excerpted from Wikipedia’s “aplindore” article, available under the CC BY-SA 4.0 licence.